...
首页> 外文期刊>Applied immunohistochemistry and molecular morphology: AIMM >De Novo Acute Myeloid Leukemia in Adults: Suppression of MicroRNA-223 is Independent of LMO2 Protein Expression BUT Associate With Adverse Cytogenetic Profile and Undifferentiated Blast Morphology
【24h】

De Novo Acute Myeloid Leukemia in Adults: Suppression of MicroRNA-223 is Independent of LMO2 Protein Expression BUT Associate With Adverse Cytogenetic Profile and Undifferentiated Blast Morphology

机译:成人从头急性髓细胞性白血病:MicroRNA-223的抑制独立于LMO2蛋白表达,但与不良的细胞遗传学特征和未分化的爆炸形态相关

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract: MicroRNA (MIR) signatures are critical to pathobi-ology and prognosis of acute myeloid leukemia (AML). MIR223 is expressed at low levels in progenitor cells, whereas high expression is induced by granulocytic differentiation. Novel-targeted therapies through epigenetic manipulation of MIR223 regulators are being explored in AML but correlative data between established clinical prognostic markers and MIR223 expression in AML is lacking. MIR223 has inverse relationship with LMO2 protein expression and our group has recently reported a close association between LMO2 protein expression and chromosomal findings in AML patients. In this study, we examined the expression of MIR223 in a large cohort of AML patients and correlated it with LMO2 protein expression, cytogenetic data, degree of differentiation [French-American and British (FAB)/ World Health Organization classifications], and overall survival. MIR223 expression was upregulated in only a subset of patients (37%). Suppression of MIR223 was more frequent among patients with aneuploid karyotype compared with diploid karyotype (P = 0.005). In AML, not otherwise specified category, AML with maturation (FAB-M2) showed higher levels of MIR223 when compared with either AML without maturation (FAB M0/M1) (P = 0.001); AML with monoblastic differentiation (FAB M4/M5) (P = 0.004) or AML with mye-lodysplasia-related changes (P = 0.011). Among cytogenetic risk groups, suppression of MIR223 was universal (> 95%) in high-risk group when compared with intermediate-risk group (P = 0.004). No correlation between MIR223 and LMO2 protein expression was identified. In conclusion, we have shown that suppression of MIR223 expression, as compared with controls, is associated with lack of differentiation and adverse cytogenetic profile, but unrelated with LMO2 protein expression or overall survival.
机译:摘要:MicroRNA(MIR)签名对于急性髓细胞性白血病(AML)的病理生物学和预后至关重要。 MIR223在祖细胞中低水平表达,而高表达是由粒细胞分化诱导的。在AML中正在探索通过表观遗传操纵MIR223调节剂的新型靶向疗法,但缺乏已建立的临床预后标志物与AML中MIR223表达之间的相关数据。 MIR223与LMO2蛋白表达呈负相关,我们的研究小组最近报道了AML患者中LMO2蛋白表达与染色体发现之间存在密切关联。在这项研究中,我们检查了一大批AML患者中MIR223的表达,并将其与LMO2蛋白表达,细胞遗传学数据,分化程度[法国-美国和英国(FAB)/世界卫生组织分类]以及整体生存率相关联。 MIR223表达仅在部分患者中上调(37%)。与非二倍体核型相比,非整倍体核型的患者中MIR223的抑制更为频繁(P = 0.005)。在AML中(未另作说明),与未成熟的AML(FAB M0 / M1)相比,成熟的AML(FAB-M2)显示更高的MIR223水平(P = 0.001);具有单细胞分化的AML(FAB M4 / M5)(P = 0.004)或具有骨髓增生相关变化的AML(P = 0.011)。在细胞遗传学风险组中,与中等风险组相比,高风险组对MIR223的抑制是普遍的(> 95%)(P = 0.004)。没有发现MIR223和LMO2蛋白表达之间的相关性。总之,我们已经表明,与对照组相比,抑制MIR223的表达与缺乏分化和不良的细胞遗传学特征有关,但与LMO2蛋白的表达或总体存活率无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号